Audio long-read: How drugmakers can be better prepared for the next pandemic
Nature Podcast
00:00
Drug Development After the Sars Epidemic
Scientists responded to the two thousand and three outbreak by designing amoe that inhibits a protein integral to corona virous replication. But infections soon petered out, and after the last cases of sars were reported in two thousand and four, fizer and other companies working on sars drugs shelved their programms. As u n c verologist timothy shehan says, it's hard to convince a company to make a drug against something that doesn't exist.
Transcript
Play full episode
